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We analyzed the expression of 13 chemokine receptors
in mycosis fungoides, in order to assess the contribution
of chemotaxis to the pathogenesis of the disease. Mate-
rial from skin biopsies of six patients with early disease
and six patients at the tumor stage of mycosis fungoides
was analyzed by immunohistochemistry and partly
also by £ow cytometry. The receptors CCR1, CCR2,
CCR3, CCR5, CCR6, CXCR1, CXCR2, CXCR5, and
CX3CR1 were rarely and inconsistently detected in le-
sional skin and thus their participation in mycosis fun-
goides could largely be ruled out. In contrast, CCR4,
CXCR3, and CXCR4 were substantially expressed on
both mycosis fungoides cells and the surrounding reac-
tive T cells in the early patch and plaque stages of the
disease, indicating an involvement of these chemokine
receptors in the disease process. In the tumor stage of
mycosis fungoides, we interestingly observed a loss
of a relevant chemokine receptor in four out of six
patients. In three patients CXCR3 and in one patient
CCR4 was absent on tumor mycosis fungoides cells,
whereas the reactive T cells showed normal levels
of expression. Within these samples, tumor mycosis
fungoides cells exhibited high levels of CCR7, a
chemokine receptor central for the entry of T cells to
lymphatic tissue. Taken together, our data suggest
that the loss of one or more of the chemokine recep-
tors involved in the homing of the mycosis fungoides
cells to the skin may trigger the latent potential of
these cells to metastasize into regional lymphatic tissue.
Key words: chemokines/cutaneous T cell lymphoma/inducible
costimulator/transformation. J Invest Dermatol 121:1045 ^1052,
2003
M
ycosis fungoides (MF) is the most common
type of cutaneous T cell lymphoma, in which a
gradual clonal expansion of atypical CD3þ
CD4þCD8^, skin-homingT lymphocytes leads
to the appearance of ‘‘patches’’ in the a¡ected
skin. These patches evolve over years to plaques. Histologically,
the patch and plaque lesions of MF characteristically present as
accumulations of band-like in¢ltrates in the papillary dermis,
with variable numbers of cells in¢ltrating the basal layer of the
epidermis (‘‘epidermotropism’’), sometimes forming ‘‘Pautrier’s
microabscesses’’. Not all cases of MF show prominent epidermo-
tropism, however, and predominantly perivascular, dermal, and
folliculotropic variants are described. MF can progress from patch
and plaque stages to dermal-based tumors, typically many years
after the initial diagnosis, and this progression correlates with a
histologic transformation to larger tumor cells. The dermal in¢l-
trate becomes more di¡use and the epidermotropism may no
longer be observed. In some patients, the tumor cells ¢nally me-
tastasize into local lymph nodes and organs. At all stages of MF,
the neoplastic in¢ltrates and the neighboring tissue contain vari-
able numbers of non-neoplastic T cells, predominantly of the
CD8þ phenotype, which are regarded as ‘‘reactive’’. The mechan-
ism underlying epidermotropism in mycosis fungoides is not
fully understood, and the same holds true for the molecular me-
chanism(s) leading to the dissemination of MF cells in the tumor
stage (Salhany et al, 1988; Greer et al, 1990; Shapiro and Pinto, 1994;
Smoller et al, 1995; Asadullah et al, 1997;Willemze et al, 1997; Nick-
olo¡, 1988).
The migration of leukocytes in the body is strongly in£uenced
by small chemotactic cytokines, the chemokines (Mackay, 2001).
Structurally, these can be subdivided into C, CC, CXC, and
CX3C chemokines, based on the pattern of the cystein residues.
Chemokines activate their target immune cells through binding
to cell surface seven-transmembrane receptors, which are
grouped, according to their ligands, into XCR, CCR, CXCR,
and CX3CR families. Homeostatic chemokines are constitu-
tively expressed and are responsible for the tra⁄cking and distri-
bution of immune cells at steady state. Malfunction of these
chemokines and their receptors can have a dramatic impact on
the integrity of the immune system (Forster et al, 1996, 1999). In
contrast to homeostatic chemokines, in£ammatory chemokines
are strongly upregulated in response to local infection, thus en-
abling a speci¢c immune response to a given pathogen (Moser
and Loetscher, 2001). Whereas the distribution and function of
chemokines and their receptors is relatively well characterized
within the lymphatic system, little is known about their contri-
bution to the organ-speci¢c tra⁄cking of immune cells (Camp-
bell et al, 1999; Kunkel et al, 2000). Even less is known about the
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expression of chemokine receptors on neoplastic cells and their
role in the dissemination of tumor cells into tissues. Recently, how-
ever, the di¡erential expression of the chemokine interferon-g-
inducible protein 10 (IP-10) was implicated in the mechanism un-
derlying epidermotropism (Sarris et al, 1995; Tensen et al, 1998).
The aim of the study was to investigate whether the dermo-
tropism and epidermotropism of neoplastic cells in MF is asso-
ciated with the expression of certain chemokine receptors.
Furthermore, we intended to determine whether the progression
of MF to the tumor stage is accompanied by a change of the che-
mokine receptor pattern on the surface of neoplastic cells. The
study was performed on skin biopsies taken from six randomly
chosen patients at the patch or plaque stages of MF, and six ran-
domly chosen patients at the tumor stage of MF. Skin biopsy spe-
cimens from all patients were examined for cells expressing the 12
chemokine receptors CCR1CCR6, CXCR1CXCR5, and
CX3CR1. The study was approved by both the Robert Koch In-
stitute and the Department of Dermatology.
MATERIALS AND METHODS
Skin biopsies and patients’ characteristics The patient material was
randomly chosen from specimens collected in the outpatient department.
The diagnosis of MF was based on clinical criteria as well as on histologic
and immunohistochemical assessment of formaldehyde-¢xed, para⁄n-
embedded skin specimens according to the European Organization for
Research and Treatment of Cancer Classi¢cation (Willemze et al, 1997).
All biopsies were taken after informed consent prior to initial treatment
or on disease relapse with absence of therapy for at least 6 mo. Staging
according to the TNM classi¢cation (Bunn and Lamberg, 1979) was based
on chest X-ray and abdominal/lymph node sonography.
Biopsies from six patients in the patch/plaque stage of MF (age range
49^80 y, median 72 y) were analyzed. TNM stage at the time of the
biopsies was assessed in two cases as T1N0M0 (patients 1 and 2) and in
four cases as T2N0M0 (patients 3^6), with one patient exhibiting a disease
progression in the course of the study (patient 2). Five patients in the tumor
stage of MF (patients 7, 8, and 10^12) and one with CD30þ large cell
pleomorphic cutaneous T cell lymphoma secondary to MF (patient 9)
were enrolled in the study (age range 36^69 y, median 59 y). Four patients
were assessed as TNM stage T3N0M0 (patients 7^10), one as T3N1M0
(patient 11), and another as T3N3M0 (patient 12). In the course of the
study, four patients in the tumor stage showed a progression of the disease
(patients 8^10 and 12), with two dying of lymphoma (patients 10 and 12).
Isolation of cells from skin biopsies Skin biopsies were placed in
sterile phosphate-bu¡ered saline after removal of ¢brous tissue and fat,
and cut into pieces of 2^3 mm. After digestion with 0.5% collagen type
VIII (Sigma, St Louis, MO), 0.1% DNAse II type IV (Sigma) diluted in
RPMI 1640 at 371C for 60 min, the cell suspension was ¢ltered through a
50 mesh metal sieve (Sigma). Cells were resuspended in 5% glucose and
tested for viability (495%) by trypan blue exclusion. In patient 8, 95%
of cells were CD3þ, 2.6% CD16þ , and 0% CD19þ. In patient 11, 52% of
cells were CD3þ, 0% CD16þ , and 47% CD19þ.
Monoclonal antibodies The following monoclonal antibodies were
used in this study: CCR1 (2D4, mouse IgG1) (Sallusto et al, 1998); CCR2
(1D9, mouse IgG2a) (Qin et al, 1996); CCR3 (7B11, mouse IgG2a (Heath et
al, 1997); CCR4 (1G1, mouse IgG1) (Andrew et al, 2001); CCR5 (2D7,
mouse IgG2a (Wu et al, 1997); CCR6 (11A9, mouse IgG1) (Sallusto et al,
1999); CCR7 (7H12, mouse IgG2b) (Campbell et al, 2001b); CXCR1
(5A12, mouse IgG2b) (Qin et al, 1996); CXCR2 (6C6, mouse IgG1) (Qin
et al, 1996); CXCR3 (1C6, mouse IgG1) (Qin et al, 1998); CXCR4 (12G5,
mouse IgG2a) (Bleul et al, 1997); CXCR4 (2B11, rat IgG2a, provided by
Dr Forster) (Forster et al, 1998); CXCR5 (BLR1, rat IgG2a, provided by
Dr Forster) (Forster et al, 1994); CX3CR1 (1E5, mouse IgG1) (Qin S,
unpublished data). If not otherwise indicated these antibodies were
puri¢ed and provided by Millennium Pharmaceuticals.
These monoclonal antibodies were validated for speci¢city of staining
on tonsillar tissue sections using immunohistochemistry and on cell
suspensions of the same tissues using £ow cytometry. The CCR7-speci¢c
monoclonal antibody did not recognize its antigen in tissue sections but
functioned well in £ow cytometry. All other chemokine receptor
monoclonal antibodies gave a consistent staining pattern in frozen tissue
sections. In addition, CCR1 and CCR3 were validated on eosinophils
using £ow cytometry.
The following murine monoclonal antibodies were used in addition:
OKT3 (CD3, IgG2a, ATCC), MPB2D5 (Vb2, IgG1, Beckman Coulter,
Fullerton, CA), IMMU 546 (Vb22, IgG1, Beckman Coulter), 91d6 (CD4,
mouse IgG2) (Szer et al, 1982),1 OKT8 (CD8, IgG2a, ATCC), B73.1 (CD16,
IgG1) (Perussia et al, 1983), BU12 (CD19, IgG1) (Flavell et al, 1995), 2A3A1H
(CD25, IgG1, ATCC), FN50 (CD69, IgG1, BD Pharmingen, San Diego,
CA), UCHL1 (CD45RO, IgG2a) (Smith et al, 1986), F44 (inducible
costimulator (ICOS), IgG1) (Hutlo¡ et al, 1999). Monoclonal antibodies
2A11 (mouse IgG1) (Beier et al, 2000), MOPC-21 (mouse IgG1, Sigma),
and 1D10 (rat IgG2a) (Mages et al, 2000) were used as isotype controls.
Immunohistochemistry Frozen tissue sections (8 mm) from skin
biopsies were ¢xed in acetone for 10 min, and incubated in 1 mM sodium
azide, 10 mM glucose, and 1U per ml glucose oxidase (Sigma) at 371C for 1
h to block endogenous peroxidase. After treatment with 0.5% blocking
solution (NEN, Boston, MA) and 10% fetal bovine serum in phosphate-
bu¡ered saline at room temperature for 1 h to inhibit unspeci¢c binding,
tissue sections were incubated with antibodies overnight at 41C, followed
by biotinylated goat-antimouse immunoglobulin or biotinylated goat-
antirat immunoglobulin (both Dianova, Hamburg, Germany). The signal
was ampli¢ed by the indirect tyramide ampli¢cation system (NEN)
according to the manufacturer’s instructions and visualized by applying 3-
amino-9-ethylcarbazole (Sigma). Nuclei were counterstained with hema-
toxylin (Merck, Darmstadt, Germany). Giemsa staining of para⁄n-
embedded sections was performed according to standard procedures. In
the analysis of the sections it had to be considered that the tyramide
ampli¢cation step by itself stained melanocytes. Para⁄n-embedded
sections from biopsies of individual MF patients were hematoxylin and
Giemsa stained and assessed for the overall in¢ltration pattern, for the
sublocalization (e.g., folliculotropism, Pautrier’s microabscesses) and
characteristics of the in¢ltrate, and for the size, shape, and regularity of
the cells and their nuclei. According to standard protocols the sections
were immunostained for a greater number of T cell and B cell markers
including CD4, CD8, CD19, CD30, CD79a, and Ki-67. The presence of
clonal T cells, a characteristic of MF cells, was determined using a panel of
T cell receptor Vb chain speci¢c monoclonal antibodies.
Flow cytometry of MF cells Cells isolated by collagenase digestion
(2.5105) were incubated with human immunoglobulin to block Fc
receptors, washed, incubated with unconjugated antibodies, washed, and
incubated with phycoerythrin-conjugated F(ab0)2 goat-antimouse
immunoglobulin (Jackson, West Grove, PA). For two-color analysis, free
binding sites were blocked with mouse g-IgG (Jackson), and the cells
were further incubated with £uorophore-conjugated monoclonal anti-
bodies. After staining, cells were analyzed on a FACSCalibur £ow cyto-
meter using 488 nm and 633 nm lasers. Dead cells were excluded by the
use of propidium iodide.
RESULTS
Discrimination of neoplastic and non-neoplastic cells in MF
biopsies We applied a number of histomorphologic criteria
to discriminate neoplastic MF cells from reactive T cells. The
morphology of the cells, such as irregular and/or hyper-
convoluted nuclei and medium to large cell size, served as
the main criterion. In addition, we considered the cell in¢ltra-
tion pattern (folliculotropism or epidermotropism, Pautrier’s
microabscesses) and at the same time the immunophenotype
(CD4, CD8, CD19, CD30, CD79a, and Ki-67) of the in¢ltrating
cells on consecutive sections. In some cases, the loss of CD3
expression and/or the expression of a predominant Vb chain all-
owed a direct identi¢cation of neoplastic cells. The independent
£ow cytometry analysis of cells isolated from lesional skin of
selected patients demonstrated that our histomorphologic
criterion for the discrimination of neoplastic cells from
in¢ltrating reactive lymphocytes was reliable.
Chemokine receptor expression in the patch and plaque
stages of MF Lesional skin biopsies from six patients with
MF at the patch or plaque stage and di¡erent tumor grading
1Szer IS, Burmeister GR, Irani A, Winchester, RJ: Two novel surface
membrane antigens on the helper T cell population. Clin Res 30: 696A,
1982 (abstr.)
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according to the TNM classi¢cation (Bunn and Lamberg, 1979)
were included in the study. Figure 1 shows the staining of an
MF lesion at the patch stage (patient 2). The CD3þ MF
in¢ltrate, shown in an overview (Fig 1A) and in detail (Fig 1B),
consisted of MF cells and reactive cells, both of which were
strongly CCR4þ and CXCR3þ (Fig 1C, E). Most of the MF
cells, but only few reactive T cells, were considered strongly
CXCR4þ (Fig 1F), and only reactive T cells were CCR6þ
(Fig 1D). No staining or very scant staining was obtained for
the chemokine receptors CCR1, CCR2, CCR3, CCR5,
CXCR1, CXCR2, CXCR5, and CX3XR1 (not shown). The
rating of chemokine receptor expression in the biopsy material
of patient 2 and the other patients in the patch or plaque stages
of MF is summarized in Table I. The comparison shows an
impressively consistent staining pattern within this patient
group. CCR6 was identi¢ed on reactive T cells only and was
seen in several biopsies (Table I). CCR1, CCR2, CCR3, CCR5
(with one exception), CXCR1, CXCR2, CXCR5, and CX3CR1
were exclusively expressed on the reactiveTcells, but the staining
was restricted to few cells and was inconsistent in this patient
group (Table I). Therefore, a direct participation of these
chemokine receptors in the pathogenesis of MF could be ruled
Figure1. Chemokine receptor expression at the plaque stage of MF
(patient 2). (A) Perivascular and epidermotropic MF in¢ltrate stained for
CD3 (original magni¢cation 100 ). (B)(G) High-power view of the region
demarcated by arrows in (A) after staining for CD3, and for the chemokine
receptors CCR4, CCR6, CXCR3, and CXCR4; also included is the stain-
ing of the same area with isotype control monoclonal antibody MOPC-21
Scale bar: (A) 100 mm; (B)(G) 50 mm.
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out. In contrast, CCR4, CXCR3, and CXCR4 were found to be
expressed on a high proportion of both MF cells and reactive
T cells, suggesting that these chemokine receptors could be
involved in the homing of both cell populations to the skin
(Table I). Importantly, none of the 12 chemokine receptors
examined was exclusively expressed on MF cells located in the
epidermis (data not shown).
Chemokine receptor expression at the tumor stage of
MF Lesional skin biopsies from ¢ve patients with de¢nitive
tumor-stage MF and from one patient with CD30þ large cell
pleomorphic cutaneous T cell lymphoma secondary to MF were
analyzed. The staining pattern obtained for chemokine receptors
at this stage of disease is well illustrated by a case in which the
MF cells have lost the CD3 marker. In this biopsy the reactive
cells could be identi¢ed by CD3 expression (Fig 2A) and were
all positive for CXCR3 (Fig 2B). Only few reactive T cells
expressed CXCR4 (Fig 2C) or CXCR5 (Fig 2D). In contrast,
the CD3^ MF cells were strongly positive for CXCR4 (Fig 2C).
Another case illustrates the approach used to identify MF cells
based on their pattern of tissue invasion. CCR4, CCR6, and
CXCR3 were expressed on neoplastic T cells located in the
follicular epithelium (Fig 3BD), CCR4 and CCR6 could be
identi¢ed on cells of a pathognomonic Pautrier’s microabscess
(inserts), and CXCR4 was strongly expressed on cells of an
epidermotropic in¢ltrate leading to an erosion (Fig 3E). A
di¡use dermal in¢ltrate was seen in the remaining four cases of
progressed MF, and a representative staining is shown in Fig 4.
Most of the large-sized tumor cells were clearly CCR4þ (Fig
4C), whereas only the reactive T cells stained positive for CCR5
and CXCR5 (Fig 4D, G). CXCR3 and CXCR4 were largely
con¢ned to small cells considered as reactive, but an absolute
distinction between tumor and reactive cells could not be made
for all cells expressing these markers in this case (Fig 4E, F). The
evaluation of chemokine receptor expression in all biopsies of
tumor-stage MF is presented in Table I. From this summary it
is apparent that the overall pattern of chemokine receptor
expression in the tumor stage of MF is similar to the pattern
found in the patch/plaque stages of MF, with prominent
expression of CCR4, CXCR3, and CXCR4 on both neoplastic
and reactive cells. A more detailed analysis, however, revealed
that in four cases out of six a selective loss of some of these
receptors occurred in the tumor stage of MF. CXCR3 was
strongly reduced or even absent on MF cells in patients 8, 9, and
11, but was highly expressed on the reactive cells in these cases.
CCR4 was no longer observed on neoplastic cells in patient 12,
but was expressed on the reactive cells. All cases with a selec-
tive loss of a chemokine receptor on tumor cells are indicated in
Table I.
Flow cytometry analysis of tumor cells and reactive cells at
the tumor stage of MF After having concluded the evaluation
of all MF tissue sections, we were able to extend the analysis in
two of the cases at the tumor stage, in which the respective clonal
TCR Vb chains on the MF cells had been determined. Using
£ow cytometry, we observed in both cases that the clonal MF
cells represented approximately half of all CD3þ cells. The
Vb22þ neoplastic cells of patient 8 were largely CD45RO^ and
CD69þ, expressed to a high degree the interleukin 2 receptor
CD25, and were partly positive for ICOS (Fig 5A), a late T cell
activation marker (Hutlo¡ et al, 1999). In patient 11, theVb2þ MF
Figure 2. Chemokine receptor expression at the tumor stage of MF
in a case of loss of CD3 on the neoplastic cells (patient 9). (A) Stain-
ing of perivascular CD3þ reactive T cells (arrows), surrounded by tumor
cells. (B)(D) Staining for chemokine receptors CXCR3, CXCR4, and
CXCR5. (E) Control staining of the same area with isotype monoclonal
antibody MOPC-21. Scale bar: (A)(E) 200 mm.
Figure 3. Chemokine receptor expression on folliculotropic and
epidermotropic tumor cells in MF (patient 7). (A) Staining for CD3
(white arrows indicate the follicular epithelium). (B) Staining for CCR4 (the
inset (400 ) shows an intradermal Pautrier’s microabscess with all cells po-
sitive for CCR4); gray arrows indicate the position of the basement mem-
brane. (C) Staining for CCR6 (inset (630 ) shows an intraepithelial
Pautrier’s microabscess with all cells positive for CCR6). (D) Staining for
CXCR3. (E) Staining for CXCR4, with tumor cell growth resulting in a
super¢cial erosion (white arrows point to the position of the basement mem-
brane). (F) Control staining with isotype monoclonal antibody MOPC-21.
Scale bar: (A)(D), (F) 100 mm; (E) 200 mm; (B) insert, (C) insert, 50 mm.
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cells were exclusively CD45ROþ, largely negative for CD25, but
expressed substantial amounts of CD69 and ICOS (Fig 5B).
When analyzed for chemokine receptors, neoplastic cells of
patient 8 were highly positive for CCR4 and CCR7 and partly
positive for CXCR4, whereas virtually all reactive cells expressed
CCR5 and CXCR3 and partly expressed CCR7 and CXCR4
(Fig 6A). A very similar picture was obtained on £ow
cytometric analysis of cells from patient 11 (Fig 6B). The
chemokine receptors CCR1, CCR2, CCR3, CCR6, CXCR1,
CXCR2, and CX3CR1 were at best marginally expressed on
the MF cells of both patients (not shown). CXCR5 expression
could not be determined in two-color £ow cytometry for
technical reasons. In both tumor MF cases, the high expression
of CCR4 and CCR7 and the absence of CCR5 and CXCR3
contrasted with the chemokine receptor expression pattern of
the reactive T cells (the few remaining Vb22þ and Vb2þ cells
not showing this expression pattern most probably represented
the expected 2%^5% of reactive T cells bearing this particular
TCR Vb chain). The £ow cytometry data were thus in very
good accordance with the results obtained independently using
Figure 4. Chemokine receptor expression in a di¡use dermal tumor
cell in¢ltrate (patient 8). (A) Staining of the in¢ltrate for CD3 (50 ).
(B) Higher magni¢cation of CD3þ Tcells with large atypical (black arrows)
or small (white arrows) nuclei. (C) Staining for CCR4, with many large cells
positive. (D) Staining for CCR5, with large cells negative. (E) Staining for
CXCR3, with large cells negative. (F) Staining for CXCR4, with large
cells partially positive. (G) Staining for CXCR5, with large cells negative.
(H) Control staining with isotype monoclonal antibody MOPC-21. Scale
bar: (A) 200 mm; (B)^(H) 50 mm.
Ta
bl
e
II
.
E
xp
re
ss
io
n
of
ch
em
ok
in
e
re
ce
pt
or
s
in
th
e
pe
ri
ph
er
al
bl
oo
d
an
d
no
rm
al
or
in
£a
m
ed
ti
ss
ue
C
he
m
ok
in
e
re
ce
pt
or
Li
ga
nd
s
E
xp
re
ss
io
n
in
th
e
pe
ri
ph
er
al
bl
oo
d
E
xp
re
ss
io
n
in
be
ni
gn
in
£a
m
m
at
or
y
in
¢
ltr
at
io
ns
an
d
no
rm
al
tis
su
e
C
C
R
4
(P
ow
er
et
al
,
19
95
)
TA
R
C
(t
hy
m
us
an
d
ac
tiv
at
io
n
re
gu
la
te
d
ch
em
ok
in
e)
(I
m
ai
et
al
,1
99
6,
19
97
)
an
d
M
D
C
(m
ac
ro
ph
ag
e-
de
ri
ve
d
ch
em
ok
in
e)
(G
od
isk
a
et
al
,1
99
7;
Im
ai
et
al
,1
99
8)
20
^3
0%
of
C
D
4
þ
T
ce
lls
;3
^5
%
of
C
D
8
þ
T
ce
ll;
no
t
ex
pr
es
se
d
by
ba
so
ph
ils
,e
os
in
op
hi
ls,
B
ce
lls
,N
K
ce
lls
(A
nd
re
w
et
al
,2
00
1)
In
¢
ltr
at
in
g
ly
m
ph
oc
yt
es
in
at
op
ic
an
d
ps
or
ia
tic
sk
in
(C
am
pb
el
le
ta
l,
19
99
;R
ot
tm
an
et
al
,2
00
1;
V
es
te
rg
aa
rd
et
al
,2
00
0)
,a
bs
en
t
fr
om
in
£a
m
ed
ga
st
ro
in
te
st
in
al
an
d
br
ai
n
tis
su
e
(C
am
pb
el
le
ta
l,
19
99
;B
al
as
ho
v
et
al
,1
99
9)
C
C
R
7
(B
ir
ke
nb
ac
he
r
et
al
,1
99
3;
B
ur
gs
ta
hl
er
et
al
,1
99
5)
SL
C
(s
ec
on
da
ry
ly
m
ph
oi
d-
tis
su
e
ch
em
ok
in
e)
(N
ag
ir
a
et
al
,1
99
7;
Yo
sh
id
a
et
al
,1
99
8)
an
d
E
LC
(E
B
I1
-l
ig
an
d
ch
em
ok
in
e)
(Y
os
hi
da
et
al
,1
99
7)
B
ce
lls
,n
a| «
ve
T
ce
lls
an
d
de
nd
ri
ti
c
ce
lls
(o
w
n
ob
se
rv
at
io
n
an
d
(M
ur
ph
y
et
al
,2
00
0)
M
aj
or
ity
of
T
ce
lls
in
th
e
je
ju
nu
m
,l
un
g
in
te
rs
tit
iu
m
,
br
on
ch
oa
lv
eo
la
r
la
va
ge
£u
id
an
d
th
e
ci
rr
ho
tic
liv
er
w
er
e
C
C
R
7
ne
ga
tiv
e.
H
al
fo
f
T
ce
lls
fr
om
no
rm
al
sk
in
as
w
el
la
s
th
e
ch
ro
ni
ca
lly
in
£a
m
ed
sy
no
vi
a
ex
pr
es
s
C
C
R
7
(C
am
pb
el
le
ta
l,
20
01
b)
C
X
C
R
4
(F
en
g
et
al
,
19
96
)
SD
F-
1
(s
tr
om
a-
de
ri
ve
d
fa
ct
or
-1
)
(B
le
ul
et
al
,1
99
7;
O
be
rl
in
et
al
,1
99
6)
M
os
t
he
m
at
op
oe
tic
ce
ll
ty
pe
s,
in
cl
ud
in
g
C
D
34
þ
pr
og
en
ito
rs
,n
eu
tr
op
hi
ls,
de
nd
ri
tic
ce
lls
,B
ce
lls
an
d
T
ce
lls
(M
ur
ph
y
et
al
,2
00
0)
an
d
al
m
os
t5
0%
of
pe
ri
ph
er
al
T
ce
lls
(B
le
ul
et
al
,1
99
7)
In
cu
ta
ne
ou
s
lu
pu
s
an
d
de
rm
at
om
yo
sit
is
al
li
n¢
ltr
at
in
g
ce
lls
be
ar
C
X
C
R
4
(P
ab
lo
s
et
al
,1
99
9)
C
X
C
R
3
(L
oe
ts
ch
er
et
al
,1
99
6)
IP
-9
(i
nt
er
fe
ro
n-
ga
m
m
a-
in
du
ci
bl
e
pr
ot
ei
n-
9)
(C
ol
e
et
al
,1
99
8)
,M
ig
(m
on
ok
in
e
in
du
ce
d
by
IF
N
)
an
d
IP
-1
0
(i
nt
er
fe
ro
n-
ga
m
m
a-
in
du
ci
bl
e
pr
ot
ei
n-
10
)
(W
en
g
et
al
,
19
98
)
R
ec
en
tly
ac
tiv
at
ed
C
D
4
þ
an
d
C
D
8
þ
T
ce
lls
,l
ow
ex
pr
es
sio
n
on
B
ce
lls
an
d
N
K
ce
lls
,a
bs
en
t
on
ne
ut
ro
ph
ils
,e
os
in
op
hi
ls
an
d
m
on
oc
yt
es
(Q
in
et
al
,
19
96
)
H
ig
h
ex
pr
es
si
on
in
ch
ro
ni
ca
lly
in
£a
m
ed
sy
no
vi
a
as
w
el
la
s
va
gi
na
la
nd
co
lo
ni
c
m
uc
os
a
(Q
in
et
al
,1
99
6)
,
br
oa
dl
y
ex
pr
es
se
d
on
T
ce
lls
fr
om
no
rm
al
je
ju
nu
m
,
ile
um
,c
ol
on
,l
un
g
an
d
br
on
ch
oa
lv
eo
la
r
la
va
ge
(K
un
ke
l
et
al
,2
00
2)
CHEMOKINE RECEPTORS IN MYCOSIS FUNGOIDES 1049VOL. 121, NO. 5 NOVEMBER 2003
immunohistochemistry (Fig 4, Table I). In particular, we were
able to con¢rm with this technique the selective loss of CXCR3
on MF cells in patients 8 and 11.
DISCUSSION
In this report we have analyzed the expression of 13 chemokine
receptors in the early patch and plaque stages as well as in the
tumor stage of MF.We sought to determine whether chemokine
receptors contribute to the characteristic localization of MF cells
in the dermis and epidermis.We were also interested to ¢nd out
whether the transition from the plaque stage to the tumor stage
of MF, in which a loss of epidermotropism can be observed, is
accompanied by a change in the chemokine receptor pattern on
MF cells. Of the examined chemokine receptors, CCR1, CCR2,
CCR3, CCR5, CCR6, CXCR1, CXCR2, CXCR5, and
CX3CR1 were absent on MF cells and at best marginally ex-
pressed on the reactive T cells, and therefore a contribution of
these receptors to the pathogenesis of MF could largely be ruled
out. In contrast, we identi¢ed an abundant expression of CCR4,
CXCR3, CXCR4, and CCR7, on both neoplastic MF cells and
reactive T cells.
The known expression characteristics of CCR4 and the re-
spective ligands are summarized inTable II.We found CCR4 to
be highly expressed on MF cells in all cutaneous compartments,
both in the patch/plaque stages and in the tumor stage. In one
case of tumor-stage MF, however, CCR4 was completely absent
(patient 12). The fraction of reactive T cells (predominantly of the
CD8 phenotype) positive for CCR4 was substantially lower
(which might be explained by the unequal distribution of
CCR4 on CD4þ versus CD8þ T cells), and further declined in
Figure 5. Flow cytometric analysis of activation cell surface markers on Tcells isolated from skin at the tumor stage of MF (patients 8 and
11). Cells were isolated from lesional skin as described in Materials and Methods and examined by £ow cytometry. For analysis, the cells were gated on the
CD3 marker. In both patients, approximately half of the CD3þ cells expressed the clonal TCRVb chains Vb22 or Vb2, respectively, and could thus be
identi¢ed as MF tumor cells, as only 2%^5% of all cells in the normal T cell repertoire express these Vb chains. Shown is the staining of tumor cells and
reactiveTcells for CD45RO, CD69, CD25, and ICOS using two-color £ow cytometry. The percentage given in the upper quadrants represents the propor-
tion of reactive T cells and tumor cells positive for the respective cell surface activation marker. (A) Patient 8; (B) patient 11.
Figure 6. Flow cytometric analysis of chemo-
kine receptors on T cells isolated from skin at
the tumor stage of MF (patients 8 and 11). Isola-
tion of cells and staining for the clonal TCR Vb
chainsVb22 andVb2 were as described in the legend
to Fig 5. Shown is the £ow cytometric analysis of
reactive T cells and tumor cells for expression of the
indicated chemokine receptors after gating on CD3.
(A) Patient 8; (B) patient 11.
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more progressed stages of the disease. The abundance of CCR4
on MF cells, in two of our cases also documented by £ow cyto-
metry, is consistent with a number of reports suggesting that this
chemokine receptor is preferentially expressed on T cells homing
to the skin. For example, the majority of CD4þ peripheral blood
T cells positive for the cutaneous lymphocyte antigen coexpress
CCR4 (Campbell et al, 1999).
The known expression characteristics of CCR7 and the
respective ligands are summarized in Table II. In our study we
were unable to determine the localization of CCR7þ cells in
the skin, as all available monoclonal antibodies fail to recognize
CCR7 in tissue sections. In the two cases analyzed by £ow cyto-
metry, however, CCR7 was strongly and uniformly expressed on
tumor MF cells, but only on 50% of the reactive T cells.
We consistently identi¢ed CXCR4 (Table II) both on MF
cells and reactive T cells, independent of the disease stage and
the sublocalization of the in¢ltrate (Table I). Stroma-derived fac-
tor 1 (SDF-1), the ligand for CXCR4 and one of the most potent
factors mediating the arrest of circulating T cells on the luminal
side of vascular endothelium before transmigration (Campbell
et al, 1998), was uniformly identi¢ed in endothelial cells of blood
vessels in nonin£amed skin (Pablos et al, 1999). In the in£amed
skin of cutaneous lupus and dermatomyositis, SDF-1 was also
identi¢ed in ¢broblasts and CXCR4 was found on the majority
of in¢ltrating mononuclear cells (Pablos et al, 1999). In view of
these data, CXCR4 seems to be an important determinant for
the localization of MF cells and reactive cells to the skin. This
homing mechanism is not speci¢c for the skin, however, as
CXCR4 is also highly expressed onTcells in the bronchoalveolar
lavage £uid of asthmatics and controls (Campbell et al, 2001a;
Kallinich et al, in preparation).
In MF, we observed a strong and consistent CXCR3 (Table II)
expression on both reactive and MF cells in the patch and plaque
stages of the disease (Table I). IP-9, the monokine induced by
interferon (Mig), and IP-10, the ligands of CXCR3, are not ex-
pressed in normal skin but are strongly upregulated in MF and
various in£ammatory skin diseases (Sarris et al, 1995; Tensen et al,
1998; 1999; Flier et al, 1999; Rottman et al, 2001). In tumor-stage
MF, we interestingly observed in two out of six cases an absence
of CXCR3 on MF cells. As documented by £ow cytometry,
this absence of CXCR3 on the neoplastic cells was accompanied
by a continuously high expression of CXCR3 on the reactive
T cells.
Several conclusions can be drawn from our data. As none of
the examined 13 chemokine receptors was exclusively identi¢ed
on MF cells, an aberrant expression of any of these receptors can
be ruled out as a cause for the homing of MF cells to the skin. In
fact, the overall expression pattern of chemokine receptors on MF
cells remarkably resembled the pattern on the reactiveTcells.This
strongly suggests that CCR4, CCR7, CXCR3, and CXCR4 are
chemokine receptors generally expressed byTcells homing to the
skin, and this view is supported by the data obtained in various
in£ammatory conditions of the skin (see Table II). The overall
concordance of the type of chemokine receptors expressed by re-
active versus MF cells supports the hypothesis that MF begins as a
reactive process from which a clone or clones with increased
growth potential emerge. The observed uniform expression of
the chemokine receptors, at least in early MF, furthermore sug-
gests that the neoplastic MF cells are still subject to regulation
by local chemokines. In fact, the expression of chemokine recep-
tors on the MF cells seems to be much more uniform than the
expression of other Tcell markers such as CD69, CD25, or ICOS,
and this potentially could be exploited for therapeutic purposes.
Regarding the characteristic epidermotropism of MF, an associa-
tion between the expression of certain adhesion molecules and
the type of epidermal in¢ltrate was described earlier (Sterry
et al, 1992; Simonitsch et al, 1994). In our study, we did not observe
any correlation to a given chemokine receptor.
We noted the absence of certain chemokine receptors in the
tumor stage of MF. As for other surface molecules, which are lost
in the more progressed stage of the disease (Ralfkiaer, 1991), the
mechanism for this phenomenon remains unclear.
Intriguing to us was the absence of CXCR3 (three patients)
and CCR4 (one patient), which we observed only in the tumor
stage of MF. We made this observation independently from a
very recent study reporting consistent expression of CXCR3 in
low-grade MF but absence of CXCR3 in the majority of cases
with progressed or transformed MF (Lu et al, 2001). At the same
time, neither we nor Lu et al observed a signi¢cant di¡erence in
the expression of a number of other cell surface markers in the
various stages of the disease. These ¢ndings seem to be relevant,
as our study revealed that CXCR3 and CCR4 are two of appar-
ently only a few determinants involved in the ‘‘localization’’ of
MF cells to the skin. An isolated absence of CCR4 or CXCR3
may not su⁄ce to ‘‘release’’ the cells from the in¢ltrate and may be
compensated by other factors. It is reasonable to assume, however,
that the absence of relevant chemokine receptor(s) alters recircu-
lation and homing of progressed MF cells. A reduced a⁄nity to
the skin may increase the number of recirculating MF cells,
thereby enabling their dissemination into other organs. In parti-
cular, the observed abundant expression of CCR7 on MF cells
would allow e¡ective homing to lymphatic tissue and could thus
be a component involved in the metastasis of MF.
We thankTumi Sherev, Department of Dermatology, ChariteŁ, Berlin, Germany, for
providing the isolated tumor cells and Dr Reinhold Foerster, Max Delbrueck Center,
Berlin, for providing antibodies against CXCR4 and CXCR5.The study was sup-
ported by a grant of the Deutsche Forschungsgemeinschaft DFG Kr827/10-4 to
R.A.K. and by the BMBF Clinical Research Unit forAllergology.
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